SCIEX expands high-throughput screening solutions with Echoâ MS+ system

The Echo® MS+ system unlocks enhanced high-throughput screening capability by bringing acoustic ejection mass spectrometry (AEMS) approaches to the SCIEX ZenoTOF 7600 system.

FRAMINGHAM, Mass.-SCIEX, a global leader in life science analytical technologies, launches the Echo® MS+ system at SLAS 2024. The system couples proprietary Acoustic Ejection Mass Spectrometry technology and Open Port Interface (OPI) sampling with the capabilities of either the SCIEX ZenoTOF 7600 or Triple Quad 6500+ system to deliver precise qualitative and quantitative results, through an expanded panel of robust high-throughput screening workflows.

The system addresses key challenges in high-throughput screening applications for drug discovery without the need for extensive method development. This is achieved through the introduction of new, flexible workflows for small and large molecules that leverage the capabilities of high-resolution mass spectrometry for improved selectivity and sensitivity compared to other analytical tools. Through a combination of high speed of analysis, high data quality and minimal sample and reagent consumption, the system has the potential to reduce the time, cost and risk in making critical decisions during the early phases of the drug development pipeline. With this expanded capability, researchers in drug discovery will have the ability to make faster and more confident decisions in hit identification and iterative lead optimization. This will help speed up the process of drug discovery and reduce the potential for false positive or false negative results.

“Building on the speed and fidelity of results that this technology can deliver by integrating it with high resolution mass spectrometry is going to enable us to develop new and novel workflows across a range of molecule types for high-throughput screening applications,” said Jose Castro-Perez, vice president of product management at SCIEX.

“Moving forward we intend to develop further new and novel workflows for the Echo® MS+ system in collaboration with customers at our global Echo® MS Center of Excellence. The goal is to address key unmet analytical needs with this disruptive technology.”

Learn more by visiting: https://sciex.com/products/integrated-solutions/echo-ms-plus

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    SCIEX. (2024, March 29). SCIEX expands high-throughput screening solutions with Echoâ MS+ system. News-Medical. Retrieved on April 27, 2024 from https://www.news-medical.net/news/20240205/SCIEX-expands-high-throughput-screening-solutions-with-Echoa-MS2b-system.aspx.

  • MLA

    SCIEX. "SCIEX expands high-throughput screening solutions with Echoâ MS+ system". News-Medical. 27 April 2024. <https://www.news-medical.net/news/20240205/SCIEX-expands-high-throughput-screening-solutions-with-Echoa-MS2b-system.aspx>.

  • Chicago

    SCIEX. "SCIEX expands high-throughput screening solutions with Echoâ MS+ system". News-Medical. https://www.news-medical.net/news/20240205/SCIEX-expands-high-throughput-screening-solutions-with-Echoa-MS2b-system.aspx. (accessed April 27, 2024).

  • Harvard

    SCIEX. 2024. SCIEX expands high-throughput screening solutions with Echoâ MS+ system. News-Medical, viewed 27 April 2024, https://www.news-medical.net/news/20240205/SCIEX-expands-high-throughput-screening-solutions-with-Echoa-MS2b-system.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.